News Novartis files CAR-T in lymphoma, sets up rivalry with Gilea... Swiss pharma to compete with Gilead in non-Hodgkin lymphoma
News Gilead gains CAR-T approval, undercuts rival's headline pric... Cancer cell therapy approved for aggressive blood cancer
News Novartis' CAR-T drug needs new payment model, says Express S... Cost of Novartis' revolutionary therapy is obstacle, says CMO.
Views & Analysis UK biotech round-up: Autolus joins CAR-T race, Horizon’s new... Three small, innovative firms demonstrate the diversity and promise of the UK bioscience sector.
News GSK takes option to develop T-cell therapy with Adaptimmune GlaxoSmithKline has jumped onto the T-cell cancer therapy bandwagon, taking an option with US biotech Adaptimmune to develop a treatment targeting a peptide found on the surface of most can
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
